{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:49:41Z","timestamp":1792648181942,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ejso.2025.110360","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T21:14:00Z","timestamp":1754428440000},"page":"110360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The role of pathological response in predicting the benefit of adjuvant therapy after neoadjuvant chemoimmunotherapy in patients with esophageal cancer"],"prefix":"10.1016","volume":"51","author":[{"given":"Maohui","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhou","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rujing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongcong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanquan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taidui","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejso.2025.110360_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ejso.2025.110360_bib2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1136\/gutjnl-2014-308124","article-title":"Global incidence of oesophageal cancer by histological subtype in 2012","volume":"64","author":"Arnold","year":"2015","journal-title":"Gut"},{"issue":"22","key":"10.1016\/j.ejso.2025.110360_bib3","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","article-title":"Preoperative chemoradiotherapy for esophageal or junctional cancer","volume":"366","author":"van Hagen","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ejso.2025.110360_bib4","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","article-title":"Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial","volume":"16","author":"Shapiro","year":"2015","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2025.110360_bib5","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","article-title":"Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial","volume":"30","author":"Qin","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejso.2025.110360_bib6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12916-023-02804-y","article-title":"Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized phase II clinical trial : a randomized clinical trial of neoadjuvant therapy for ESCC","volume":"21","author":"Li","year":"2023","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.ejso.2025.110360_bib7","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/JS9.0000000000000816","article-title":"Comparison of efficacy and safety between neoadjuvant chemotherapy and neoadjuvant immune checkpoint inhibitors combined with chemotherapy for locally advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis","volume":"110","author":"Xu","year":"2024","journal-title":"Int J Surg"},{"issue":"13","key":"10.1016\/j.ejso.2025.110360_bib8","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejso.2025.110360_bib9","doi-asserted-by":"crossref","first-page":"393","DOI":"10.6004\/jnccn.2023.0019","article-title":"Esophageal and esophagogastric junction cancers, version 2.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Ajani","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"11","key":"10.1016\/j.ejso.2025.110360_bib10","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C","article-title":"Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations","volume":"73","author":"Mandard","year":"1994","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2025.110360_bib11","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/j.ejso.2017.03.001","article-title":"Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: a meta-analysis of 17 published studies","volume":"43","author":"Tomasello","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2025.110360_bib12","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1245\/s10434-019-07967-8","article-title":"Prognostic value of tumor regression grade based on ryan score in squamous cell carcinoma and adenocarcinoma of esophagus","volume":"27","author":"Takeda","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2025.110360_bib13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1245\/s10434-020-09181-3","article-title":"Clinical utility of ypTNM stage grouping in the 8th edition of the American joint committee on cancer TNM staging system for esophageal squamous cell carcinoma","volume":"28","author":"Sudo","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2025.110360_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100385","article-title":"Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study","volume":"7","author":"Park","year":"2022","journal-title":"ESMO Open"},{"issue":"4","key":"10.1016\/j.ejso.2025.110360_bib15","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41379-019-0393-7","article-title":"Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey","volume":"33","author":"Westerhoff","year":"2020","journal-title":"Mod Pathol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110360_bib16","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1002\/onco.13707","article-title":"College of American pathologists tumor regression grading system for long-term outcome in patients with locally advanced rectal cancer","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ejso.2025.110360_bib17","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.ejso.2015.07.010","article-title":"Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: postoperative chemotherapy has a substantial impact on outcome","volume":"41","author":"Glatz","year":"2015","journal-title":"Eur J Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2025.110360_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1002\/jso.24601","article-title":"The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery","volume":"115","author":"Saunders","year":"2017","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2025.110360_bib19","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.7150\/thno.80091","article-title":"Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy","volume":"13","author":"Yin","year":"2023","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.ejso.2025.110360_bib20","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.ymthe.2024.09.026","article-title":"PD-L1: from cancer immunotherapy to therapeutic implications in multiple disorders","volume":"32","author":"Lee","year":"2024","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.ejso.2025.110360_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jtcvs.2009.10.003","article-title":"Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer","volume":"139","author":"Stiles","year":"2010","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.ejso.2025.110360_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/SLA.0000000000005227","article-title":"Role of adjuvant therapy in esophageal cancer patients after neoadjuvant therapy and esophagectomy: a systematic review and meta-analysis","volume":"275","author":"Lee","year":"2022","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2025.110360_bib23","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1097\/SLA.0000000000005679","article-title":"Adjuvant therapy after neoadjuvant therapy for esophageal cancer: who needs it?","volume":"278","author":"Raja","year":"2023","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.ejso.2025.110360_bib24","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.jtcvs.2018.05.100","article-title":"Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival","volume":"156","author":"Samson","year":"2018","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"10.1016\/j.ejso.2025.110360_bib25","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/SLA.0000000000001954","article-title":"Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer","volume":"266","author":"Burt","year":"2017","journal-title":"Ann Surg"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325007887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798325007887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:13:36Z","timestamp":1772792016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798325007887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0748798325007887"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110360","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of pathological response in predicting the benefit of adjuvant therapy after neoadjuvant chemoimmunotherapy in patients with esophageal cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2025.110360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110360"}}